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Despite the recent advances in anti-cancer therapies, breast cancer accounts for the highest percentage of estimated new cases 
among female cancer patients. The anti-cancer drug Ukrain, a plant-derived semi-synthetic compound, has been shown to be ef-
fective in a variety of tumor models including colon, brain, ovarian, melanoma and lymphoma. However, the direct cytotoxic effects 
of Ukrain have yet to be investigated in breast cancer models. Aim: Herein, we investigated the in vitro and in vivo cytotoxicity 
of Ukrain using murine (4T07 and TUBO) and human (SKBR-3) breast cancer cell lines. Methods: Cells were treated with vary-
ing concentrations of Ukrain for up to 72 h and analyzed for viability by trypan blue exclusion, apoptosis by intracellular caspase 
3 and Annexin V staining, and proliferative potential by a clonogenic assay. Female BALB/c mice were challenged subcutane-
ously (s.c.) with 4T07-RG cells and administered 5 mg/kg or 12.5 mg/kg body weight Ukrain intravenously (i.v.) on the same day 
and 3 days later. Protective immune responses were determined following re-challenge of tumor-free mice 35 days post primary 
challenge. Results: Ukrain exposure induced apoptosis in a dose and time-dependent manner with 50 µg/mL Ukrain leading to 
>50% cell death after 48 h exposure for all three breast cancer cell lines. Ukrain administration (12.5 mg/kg) led to significant 
inhibition of 4T07 tumor growth in vivo and sustained protective anti-tumor immunity following secondary challenge. Conclusion: 
Our findings demonstrate the in vitro and in vivo cytotoxic effects of Ukrain on breast cancer cells and may provide insight into 
designing Ukrain-based therapies for breast cancer patients.
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Cancer is among the leading causes of mortality 
in the United States, second only to heart diseases [1]. 
While the mortality rates associated with many other 
diseases have seen a significant decline in the past 
50–60 years, a similar reduction has yet to be seen 
in the cancer field [2]. These statistics speak to the 
overwhelming necessity to develop more effective 
treatment options for cancer patients. Closer examina-
tion of these statistics contribute to the high mortality 
reveals that breast cancer is the second leading cause 
of cancer-related deaths among women and accounts 
for the highest percentage of estimated new cancers 
among female cancer patients [3]. While several treat-
ment options are currently available to cancer patients 
such as surgery, chemotherapy and radiation therapy 
either alone or in an adjuvant setting, each approach 
is associated with a wide range of clinical challenges. 
The most significant drawback to chemotherapeutic 
drugs, the most widely used anti-cancer treatment 
option, is their toxicity towards non-malignant cells [4]. 
The anticancer drug Ukrain (NSC 631570), a semi-
synthetic compound derived from the extract of the 
plant Chelidonium majus L., has been shown to exert 
selective cytotoxic effects towards a variety of malig-
nant cells including colon, brain, ovarian, melanoma 
and lymphoma without harmful side effects on healthy 
human cells [5, 6]. The cytotoxic selectivity of Ukrain 
is thought to be based on the differential membrane 
potentials of malignant cells and normal cells. It has 
been reported that the positive charge of the celandine 
alkaloids comprising the Ukrain allows malignant cells 
to absorb more Ukrain than healthy cells [7].
To date several clinical trials have assessed the 
efficacy of Ukrain in patients with an assortment 
of malignancies such as colorectal, pancreatic, blad-
der and breast cancers [8]. In each of these trials, 
patients treated with Ukrain had a more favorable 
clinical response compared to control groups (pla-
cebo or other therapies) which included either longer 
survival [9], extended periods of non-progression [10] 
and/or symptomatic improvements [11]. Previously, 
two groups [12, 13] have assessed the potential effects 
of Ukrain in breast cancer models citing that Ukrain fails 
to enhance the radiosensitivity of MDA-MB-231 human 
breast cancer cells and Ukrain treatment can enhance 
the cytolytic activity of peritoneal exudate macro-
phages towards DA-3 mammary tumor cells. However, 
to the best of our knowledge, a thorough investigation 
of the direct cytotoxic effects of Ukrain on a variety 
of breast cancer cells has yet to be reported.
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Herein, we demonstrate the in vitro effectiveness 
of Ukrain to selectively kill both mouse and human 
breast cancer cells. Additionally in vivo experiments 
indicate that Ukrain can induce tumor inhibition 
in a breast cancer model and for the first time that 
Ukrain can induce protective antitumor immunity. 
Taken together, our findings provide evidence of the 
effectiveness of Ukrain in breast cancer models.
MATERIALS AND METHODS
Cell lines. The 4T07 cell line, a non-metastatic 
clone derived from a spontaneous adenocarcinoma 
in BALB/cfC3H mice (410.4), was a kind gift from 
Fred Miller (Wayne State University) [14]. While cells 
can be recovered from the lungs of mammary pad 
inoculated mice, 4T07 fails to colonize the lungs and 
form metastatic nodules [15]. TUBO cells, derived from 
a spontaneous carcinoma in BALB-neuT mice [16], 
are also non-metastatic and were provided by John C. 
Morris (National Institutes of Health). The 4T07, TUBO 
and NIH 3T3 (mouse embryonic fibroblasts) cell lines 
were cultured in DMEM F12 media, supplemented with 
10% cosmic calf serum (Hyclone, Logan, Utah) and 
1% penicillin streptomycin (Mediatech, Manassas, 
VA). The human breast cancer cell line, SKBR-3, was 
cultured in RPMI 1640 media supplemented with 10% 
cosmic calf serum and 1% penicillin streptomycin and 
was obtained from American Type Culture Collection 
(ATCC, Manassas, VA). The TUBO and SKBR-3 cell 
lines constitutively express the HER-2/neu oncogene, 
which is overexpressed in 30% of human breast cancer 
patients. All cells were maintained at 37oC in a humidi-
fied 5% C02 incubator.
Mouse model. Female BALB/c mice (8–12 week 
old) were purchased from Jackson Laboratories (Bar 
Harbor, Maine) and used for all in vivo studies. Mice 
were housed and maintained according to institutional 
guidelines and protocols approved by the Institutional 
Animal Care and Use Committee (IACUC) for Emory 
University in Atlanta, GA. 
Reagents. Ukrain was kindly provided by Dr. 
Wassil J. Nowicky and Stephen Karoly from Nowicky 
Pharma (Vienna, Austria). The stock solution was sup-
plied at a concentration of 1 mg/mL. Apoptosis was as-
sessed using the Annexin V-FITC Apoptosis Detection Kit 
(Sigma, St. Louis, MO), BD Cytofix/Cytoperm Fixation 
and Permeabilization solution and FITC rabbit anti-active 
caspase-3 antibody (BD Pharmingen, La Jolla, CA). 
Antibodies used to phenotype isolated splenocytes 
by flow cytometry included anti-CD4-FITC, anti-CD8-
FITC, anti-B220-PE, anti-CD11b-FITC, anti-Gr-1-PE and 
CD16/32 Fc-block (eBioscience, San Diego, CA).
In vitro drug treatment assay. Murine and human 
breast cancer cells were seeded at a density of 5x104 cells 
per well in 24-well plates (in duplicate) in appropriate cul-
ture media. After being allowed to adhere, tumor cells 
were treated with 0; 25; 75; 100 µg/mL Ukrain for 24; 
48 and 72 h. At the specified time point, cells were ana-
lyzed for viability, apoptosis, and clonogenic potential. 
As specificity controls, concanavalin A (ConA)-stimulated 
mononuclear cells, isolated from the spleens of naive 
BALB/c mice and recovered by Ficoll-Hypaque density 
centrifugation, and NIH 3T3 cells were treated with Ukrain 
at the aforementioned concentrations for 24, 48, and 
72 h and cellular viability was subsequently assessed 
by the trypan-blue exclusion method.
Detection of apoptosis using Annexin V, 
PI staining. Ukrain-treated cells were washed once with 
PBS, re-suspended in 1X Binding Buffer and Annexin 
V-FITC (5 µL) and Propidium Iodide-PE (10 µL) (Sigma, 
St. Louis, MO) was added to each cell suspension. Cells 
were incubated for 10 minutes at room temperature 
in the dark. Staurosporine, 2.5 µM, (Sigma) was used 
as a positive control for apoptosis induction. Stained 
cells were analyzed immediately using a FACSCaliber 
(Beckman Coutler, Fullterton, CA) and Flowjo software.
Quantification of active caspase-3. Following 
Ukrain treatment, cells were washed, fixed and perme-
abilized for 20 min at 4 oC using BD cytofix/cytoperm 
solution (BD Pharmingen). Permeabilized cells were 
washed and stained for intracellular caspase-3 using 
the FITC rabbit anti-active caspase-3 antibody (clone 
C92–605) for 30 min at 4 oC in the dark (BD Pharmin-
gen). Cells were then analyzed using flow cytometry 
as described previously.
Clonogenic assay. The long-term effects of Ukrain 
treatment on murine and human breast cancer cells 
were assessed using a clonogenic assay. Following 
24; 48 and 72 h treatment with Ukrain, cells were plated 
in 60 mm tissue culture plates at 100 cells/plate. Cells 
were allowed to form colonies for two weeks. The 
colonies were then gently washed with PBS, fixed and 
stained with crystal violet (0.5% w/v in 90% ethanol) 
and counted by light microscopy. The surviving fraction 
of colonies was calculated as previously described [17].
Tumor growth inhibition studies. 4T07 cells were 
passaged 4 times in vivo to obtain reproducible tumor 
growth with palpable tumor development within 6 days 
(4T07RG). To assess the in vivo cytotoxicity of Ukrain 
in a mouse model, female BALB/c mice were chal-
lenged subcutaneously (s.c.) with 5x104 4T07RG cells 
on the shaved right hind flank. Mice were then admin-
istered 5mg/kg or 12.5 mg/kg body weight Ukrain via 
tail vein injection (i.v.) on the same day. The mice were 
then administered an additional dose of Ukrain 3 days 
later. Tumors were measured 2–3 times a week using 
a Vernier caliper. Mice were sacrificed once the tumors 
became ulcerated or exceeded 1 cm2 in diameter. 
At the conclusion of the experiment (day 35), tumor-
free mice were re-challenged with 5x104 4T07RG cells 
and monitored for tumor growth for an additional 
35 days to determine whether Ukrain is capable of in-
ducing protective antitumor immunity.
Cellular phenotyping of splenocytes. Spleens 
were harvested and weighed from Ukrain treated mice 
on day 35 following re-challenge with 4T07RG cells. Sin-
gle cell suspensions were prepared and red blood cells 
were removed by hypotonic lysis. Splenocytes were 
then washed in FACS buffer (PBS/1%CCS/1%EDTA), 
incubated in Fc block (CD16/32, clone 2.4G2) and 
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stained for 25 minutes at 4 oC with the appropriate an-
tibodies to detect T cells (CD4 and CD8), B cells, and 
myeloid derived suppressor cells (MDSCs). Antibodies 
used for analysis were anti-CD4-FITC, anti-CD8-FITC, 
anti-B220-PE, anti-CD11b-FITC, anti-Gr-1-PE. Sample 
readings were collected using a FACSCaliber and ana-
lyzed with Flowjo software.
Statistical analysis. All in vitro experiments were 
performed in duplicate or triplicate and were repeated 
at least twice. Differences between caspase-3 ac-
tivation following Ukrain treatment as well as tumor 
growth curves were assessed using ANOVA analysis. 
For survival curves, P values were determined using 
the Log-rank (Mantel — Cox) test. P < 0.05 was consi-
dered statistically significant. All graphs and statistical 
calculations were done using GraphPad Prism software 
(GraphPad Software Inc., San Diego).
RESULTS
Ukrain exhibits cytotoxic effects specifically 
on breast cancer cells not non-malignant cells. 
Human and murine breast cancer cells were treated 
with 25; 50; 75 and 100 µg/mL Ukrain for 24; 48 and 
72 h. At each time-point, viability was determined 
using the trypan-blue exclusion method. We began 
to observe morphological changes of all three breast 
cancer cell lines after 48 hours of Ukrain exposure. The 
Ukrain-treated cells began to shrink in size, undergo 
membrane blebbing, loose cell-to-cell contact and ad-
herence to the tissue culture plate (Fig. 1a). Additional-
ly, we observed a dose and time-dependent decrease 
in viability with 50 µg/mL Ukrain leading to 50% cell 
death after 48 h exposure for all three breast cancer 
cell lines tested (Fig.1b). Following 72 h Ukrain expo-
sure at 100 µg/mL maximal cell death was observed 
with the viability of 4T07, TUBO and SKBR-3 cells being 
12.9%, 17.53% and 30.8% respectively. As specifi-
city controls, mouse fibroblasts (NIH 3T3 cells) and 
ConA-stimulated mononuclear cells were treated with 
similar doses of Ukrain. We observed minimal cytotoxic 
effect of Ukrain on mouse fibroblast cells (Fig.1c) and 
ConA-stimulated lymphocytes (data not shown) even 
at higher exposure doses with the viability remaining 
above 90%. These findings indicate that the cytotoxic 
effects of Ukrain are specific to the breast cancer cells 
while not affecting non-malignant cells. 
Ukrain treated tumor cells fail to regain pro-
liferative capacity. To determine whether Ukrain 
treated cells have a reduced ability to proliferate, a clo-
nogenic assay was conducted. Following Ukrain treat-
ment for 24; 48 or 72h, cells were washed and replated 
in fresh culture media lacking Ukrain. After two weeks 
of culture, colonies were washed, stained with crystal 
violet and counted by light microscopy. The surviving 
fraction is defined as the number of colonies derived 
from pre-treated tumor cells following two week 
removal of Ukrain expressed in terms of plating ef-
ficiency as previously described [17]. The pre-treated 
cells showed a reduced ability to form colonies relative 
to untreated cells (Fig. 2). Follo wing 24 h pre-treatment 
with 50 µg/mL Ukrain, 4T07, TUBO and SKBR-3 tu-
mor cells exhibited a comparable inability to form 
colonies with surviving fractions of 0.0024, 0.0039 and 
0.0019 respectively. Minimal differences were ob-
served in the surviving fractions of 4T07 and TUBO 
cells exposed to 50 µg/mL Ukrain for 24, 48 or 72 h. 
However, 72 h exposure to 50 µg/mL Ukrain led to a 10-
fold reduction in the surviving fraction of SKBR-3 cells 
(0.000135) relative to 24 h and 48 h from exposure 
from 0.0019 and 0.001315, respectively. Both murine 
and human breast cancer cells that were pre-treated 
with Ukrain for 72 h with 100 µg/mL Ukrain, were un-
able to form any visible colonies (denoted by †). This 
data illustrates the long-term effects of Ukrain treat-
ment on the clonogenic potential of breast cancer 
cells and indicates that upon removal of Ukrain, the 
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Fig. 1. Dose and time dependent cytotoxic effects of Ukrain 
on breast cancer cells. a) Morphological changes are observed 
for murine and human breast cancer cells following 48 hr exposure 
to Ukrain by light microscopy (10X magnification). b) Following 
24; 48; 72 hr Ukrain exposure, the viability of b) murine (4T07 and 
TUBO) and human (SKBR-3) breast cancer cells and c) mouse 
fibroblast cells were assessed for viability by trypan blue exclu-
sion. Data shown is mean ± SD of three individual experiments
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treated tumor cells are unable to recover from the 
drug’s cytotoxic effects.
Ukrain exerts anti-tumor activity through apop-
tosis induction. Ukrain has previously been shown 
to induce apoptosis of Jurkat T cell lymphoma through 
mitochondrial membrane depolarization and caspase 
activation [18] and HeLa cervical cancer cells through the 
activation of the intrinsic pathway (caspase-9 cleavage) 
[19] . Therefore to investigate whether the observed cyto-
toxic effects of Ukrain on breast cancer cells are due to the 
induction of apoptosis we carried out an Annexin-V binding 
assay as well as intracellular staining for active caspase-3. 
As shown in Fig. 3a, there was a 10–15 fold increase 
in activated caspase-3 among 4T07 and TUBO cells and 
a 2–3 fold increase among SKBR-3 within 48 h of drug 
exposure. Similarly, 80–90% of the Ukrain-treated tumor 
cells were apoptotic as indicated by AnnexinV/PI dual 
staining after 48h (Fig. 4a). The kinetics of apoptosis 
induction indicates a dose and time dependent increase 
in activated caspase 3 and Annexin V/PI staining (Fig. 3b 
and 4b). Our findings indicate apoptosis as the cytotoxic 
mechanism of action which is consistent with previous 
reports in other tumor model systems [18–21].
Systemic administration of Ukrain significantly 
reduces breast cancer tumor growth in mice. 
To assess the in vivo efficacy of Ukrain in causing tumor 
inhibition in a murine breast cancer model, mice were 
challenged with 5x104 4T07RG cells (s.c.) and adminis-
tered varying doses of Ukrain (5 mg/kg or 12.5 mg/kg) 
on the same day (i.v.). Three days later, mice received 
an additional dose of Ukrain (i.v.). It has previously 
been reported that following subcutaneous or intra-
peritoneal injection of Ukrain, no inhibitory effect 
on the growth of established DA-3 mammary adeno-
carcinoma was observed whereas significant inhibition 
was observed following intravenous Ukrain administra-
tion [12]. We observed that treatment with two doses 
of 12.5 mg/kg Ukrain led to a significant reduction 
in overall tumor burden by day 31 relative to untreated 
mice with an average tumor burden of 22.7 mm2 com-
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Fig. 2. Survival Fractions following Ukrain treatment. Following 
24; 48 and 72 h exposure, Ukrain treated cells were plated for two 
weeks to allow for colony formation. Colonies were washed, fixed 
and stained with crystal violet and counted by light microscopy. 
The surviving fraction was then calculated as the ratio of the 
plating efficiency of drug-treated cells to the plating efficiency 
of untreated cells. (†) denotes a surviving fraction of zero. Data 
shown is mean ± SD of two individual experiments 
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Fig. 3. Ukrain induces the activation of intracellular cas-
pase-3 in a dose and time dependent manner. Following Ukrain 
treatment, cells were washed, fixed, permeabilized and stained 
for intracellular caspase 3 with FITC rabbit anti-active cas-
pase-3 antibody a) Representative plots of intracellular caspase 
3 activation following 48 h Ukrain exposure by flow cytometry. b) 
Dose response and kinetics of intracellular caspase 3 activation 
following 24 h and 48 h Ukrain treatment. Data shown is mean ± 
SD of two individual experiments. Statistical analyses of caspase 
3 activation P values were calculated using ANOVA. (*) p < 0.05, 
(**) p<0.01, (***) p< 0.001 relative to untreated
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pared to 78.9 mm2 for untreated mice (Fig. 5a). While 
all mice had palpable tumors by day 7 post challenge, 
we began to observe the effects of the Ukrain treat-
ment regimes on day 14 post challenge (11 days after 
the last Ukrain administration). The mice that received 
5 mg/kg Ukrain, on average, also had smaller tumors 
that developed more slowly than the untreated mice 
with a mean tumor burden of 47.7 mm2. By the end 
of the experiment, tumors in several mice treated with 
5 mg/kg and 12.5 mg/kg had completely regressed 
with tumor incidences being 60 and 40%, respectively 
(Fig. 5b). Importantly, we observed no visible signs 
of morbidity such as weight loss among the Ukrain 
treated groups (Fig. 5c). Interestingly, when the Ukrain 
dose was increased to 20 mg/kg, the treated mice 
failed to be protected and developed progressive 
tumor growth similar to the untreated mice (data not 
shown). While 25 mg/kg Ukrain has been reported 
to effectively inhibit metastases of murine Lewis 
lung carcinoma [22], our observation suggests that 
similarly high doses of Ukrain may not be effective 
in vivo in breast cancer models. Taken together, these 
findings indicate that moderate doses of Ukrain can 
inhibit tumor progression and induce tumor regression 
in a highly tumorigenic mouse breast cancer model.
Ukrain treatment induces protective immunity. 
Next, to determine whether Ukrain administration 
can provide protection against a secondary tumor 
challenge, thirty-five days post initial challenge, 
tumor-free mice from each Ukrain-treated group were 
re-challenged with 5x104 4T07RG cells. We observed 
that all mice remained tumor free up to day 35 post 
re-challenge indicating that protective immunity was 
induced following Ukrain treatment (Fig. 6a).
Interestingly, we observed that untreated, tumor-
bearing mice developed significant splenomegaly 
(1.16 g) relative to the Ukrain treated mice (0.1 g) 
whose spleens were comparable in size and weight 
to naïve, unchallenged mice (Fig. 6b, photograph). 
To gain insight into potential immune modulatory 
effects of Ukrain that could be responsible for the 
observed protective immunity, we conducted cel-
lular phenotyping of cells that were found within the 
spleens of Ukrain treated mice. Previous reports have 
shown that splenomegaly in the 4T1 mouse breast 
cancer model, derived from the same parental clone 
as 4T07, to be associated with an increased infiltration 
of myeloid derived suppressor cells (MDSCs) [23]. Our 
observations indicate that in the 4T07 tumor model 
system, wild-type challenged mice develop a similar 
splenomegaly which correlates with a 12–15 fold in-
crease in the percentage of CD11b+Gr-1+ MDSCs rela-
tive to the Ukrain treated, tumor-free mice (Fig. 6c). 
Interestingly, when we compared the percentage 
of MDSCs in naïve mice to the Ukrain-treated, tumor-
free mice, we noticed a 2–3 fold decrease in the 
splenic population of these cells. Taken together, these 
studies demonstrate that Ukrain treatment results 
in persistent protective immunity in a highly immuno-
suppressive and tumorigenic breast cancer model.
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Fig. 4. Cytotoxic effects of Ukrain is mediated by apoptosis. Ukrain 
treated cells were washed and stained with Annexin-V-FITC and 
PI-PE and analyzed by flow cytometry. a) Representative plots 
of Annexin V/PI staining following 48 h Ukrain exposure by flow 
cytometry. b) Mean ± SD of two individual experiments. b) Dose 
response and kinetics of Annexin V/PI staining following 48 h and 
72 h Ukrain treatment. Mean ± SD of two individual experiments
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DISCUSSION
The anticancer drug Ukrain has been assessed for 
potential clinical efficacy in Europe in patients suffering 
from colorectal, pancreatic, bladder and breast cancers 
as reviewed in [8]. In vitro studies have demonstrated the 
anti-proliferative and cytotoxic effects of Ukrain in a wider 
variety of tumor models including colon, brain, ovarian, 
Ewing, melanoma, lymphoma and glioblastoma cell 
lines [5, 24–27]. The property that distinguishes Ukrain 
from typical therapies, such as radiation therapy and 
chemotherapy, lies in its unique ability to specifically 
target and kill malignant cells while leaving healthy cells 
unharmed [5]. However, the direct anti-tumor effects 
of Ukrain in breast cancer models remain obscure. 
Therefore, in this report we investigated the in vitro and 
in vivo efficacy of Ukrain in murine and human breast 
cancer models. Consistent with previous reports in other 
tumor models, we observed that Ukrain induces apopto-
sis of breast cancer cells through caspase 3 activation. 
Additionally, after a short exposure time, 24 h, Ukrain 
treated cells have reduced clonogenic potential in the 
absence of the drug and are unable to form colonies 
following longer exposure (72h) at 100 µg/mL Ukrain. 
Most importantly, in vitro cytotoxicity is translatable in vivo 
in the form of significant tumor inhibition and regression. 
Interestingly, we observed that Ukrain is also capable 
of inducing protective anti-tumor immune responses 
which is consistent with clinical observations of patients 
achieving sustained/long-term remissions for years fol-
lowing Ukrain treatment [28–30].
At present, the mechanism(s) responsible for these 
protective anti-tumor responses induced by Ukrain re-
main unclear. However, it is possible that Ukrain could 
potentially be working through two related mecha-
nisms: 1) direct cytotoxic effects on tumor cells lead-
ing to a significant reduction in overall tumor burden 
and 2) as a result of the direct killing of tumor cells, 
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Fig. 5. Ukrain administration led to significant tumor inhibition. 
Mice (n=10) were challenged with 5x104 4T07RG cells. Ukrain was 
administered (i.v.) on the same day and day 3 post challenge. 
a) Average tumor size of mice treated with Ukrain. b) Tumor 
incidence c) Average Body Weight. Statistical analyses of tumor 
growth P values were calculated using one-way ANOVA. (*) 
p < 0.05 relative to untreated. Data shown is mean ± SEM. Rep-
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Fig. 6. Ukrain administration induced protective anti-tumor im-
munity. On day 35 post primary challenge, Ukrain treated, tumor-
free mice (n=10) were re-challenged with 5x104 4T07RG cells 
and monitored for an additional 35 days for tumor development 
(a). On day 35 post re-challenge, spleens were harvested from 
Ukrain treated mice and analyzed for MDSCs (CD11b+, Gr-1+). 
Protective immunity induced by Ukrain correlates with a reduced 
spleen weight (b) and reduced prevalence of splenic MDSCs (c) 
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antigen-presenting cells such as dendritic cells (DCs) 
could endocytose tumor-derived apoptotic bodies 
and in turn elicit a robust tumor-specific CTL response 
as reported in other tumor models [31]. The induction 
of “immunogenic cell death” has been demonstrated 
following treatment with chemotherapeutic agents such 
as doxorubicin and cyclophosphamide such that due 
to their enhanced antigenicity, apoptotic tumor cells 
are more efficiently phagocytosed by DCs [32, 33]. 
The characteristics of immunogenic apoptosis of can-
cer cells include: phosphatidylserine (PS) exposure, 
caspase activation, and mitochondrial depolarization 
[34]. Additionally, this type of cell death is associated 
with the surface expression of certain molecules includ-
ing calreticulin and HSP90 as well as the ability to elicit 
a protective immune response against tumor cells [35, 
36]. As we observed in our studies, Ukrain treatment led 
to the activation of effector caspase 3 and PS surface 
expression as detected by positive Annexin-V stain-
ing in all three breast cancer models tested in vitro. 
Further, Ukrain has been shown to induce mitochon-
drial deplorization in Jurkat cells [18]. Our study also 
demonstrated the in vivo efficacy of 5 mg/kg and 
12.5 mg/kg Ukrain administration in the form of tumor 
inhibition and protective immunity. However, at a higher 
dose, 25 mg/kg, these responses were not observed 
which suggest the induction of a less immunogenic, 
potentially tolerogenic, form of cell death as reported 
following treatment with other anticancer drugs such 
as alkylating agents and cisplatin [36, 37]. Taken to-
gether our findings, along with others, are in support 
of the potential induction of immunogenic tumor cell 
death following “low dose” Ukrain treatment. 
Alternatively, Ukrain could also act directly on im-
mune cells and thus mediate the induction of anti-tumor 
immune responses. It has been reported that Ukrain 
can enhance the cytolytic activity of macrophages 
and lymphocytes in vitro [12, 38]. We observed that 
following secondary challenge, Ukrain treated mice re-
mained tumor free, failed to develop splenomegaly and 
correspondingly had a significantly lower prevalence 
of splenic MDSCs relative to untreated mice. Addition-
ally, the Ukrain treated mice had increased percentages 
of CD4+, CD8+ and B220+ cells in the spleen relative 
to the untreated, tumor-bearing mice (data not shown). 
Interestingly, we also observed a 2–3 fold decrease 
in the percentage of MDSCs in the spleens of Ukrain 
treated mice when compared to naïve mice. These find-
ings suggest that Ukrain could potentially inhibit the ex-
pansion of splenic CD11b+Gr-1+ MDSCs thus reducing 
the overall level of immune suppression present within 
the treated mice. This reduction in immune suppression 
could ultimately lead to protection against subsequent 
challenge and the splenomegaly observed in untreated, 
tumor-bearing mice. While chemotherapeutic drugs, 
namely gemcitabine and 5-fluorouracil, have been 
shown to effectively deplete MDSCs [39, 40], additional 
studies would be needed to determine whether Ukrain 
has any direct effects on this immune suppressive cell 
population in vivo particularly in tumor-bearing mice.
Taken together, our findings provide insight into 
the direct cytotoxic effects of Ukrain on breast cancer 
cells and the in vivo efficacy of Ukrain administration 
on the reduction of overall tumor burden and the induc-
tion of protective antitumor immunity. Based on these 
observations, it is likely that the immune modulatory 
effects following Ukrain administration in vivo are a re-
sult of enhanced phagocytosis of apoptotic tumor 
cells either alone or in combination with direct effects 
on the relative abundance/prevalence of effector and 
suppressive immune cell populations.
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